Patents by Inventor Gordon Saxty

Gordon Saxty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331720
    Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 19, 2023
    Inventors: Bruce LEFKER, Gordon SAXTY, Karl GIBSON, Mark PICKWORTH, Matthew SPENDIFF, Miles Stuart CONGREVE, Paul HUMPHRIES
  • Publication number: 20230227450
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 20, 2023
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • Patent number: 11643410
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 9, 2023
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • Patent number: 11512096
    Abstract: The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.
    Type: Grant
    Filed: December 24, 2020
    Date of Patent: November 29, 2022
    Assignee: SELVITA D.O.O.
    Inventors: Andrea Fajdetic, Maja Matanovic Skugor, Ivaylo Jivkov Elenkov, Goran Kragol, Mirjana Bukvic, Zorica Marusic Istuk, Sanja Kostrun, Dinko Ziher, Renata Rupcic, Kristina Butkovic, Marko Duksi, Ivana Ozimec Landek, Dijana Pesic, Antun Hutinec, Milan Mesic, Gordon Saxty, Visnja Poljak
  • Publication number: 20220204503
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 30, 2022
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • Publication number: 20220169653
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: June 2, 2022
    Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
  • Publication number: 20220135544
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 11225476
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: January 18, 2022
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • Patent number: 11136325
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 5, 2021
    Assignee: GALAPAGOS NV
    Inventors: David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
  • Publication number: 20210238162
    Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 5, 2021
    Inventors: Rodolfo CADILLA, David Norman DEATON, Ashley Paul HANCOCK, Heather HOBBS, Simon Teanby HODGSON, Andrew L. LARKIN, Joelle LE, Paul N. MORTENSON, Daniel J. PRICE, Gordon SAXTY, Lee T. SCHALLER, Christie SCHULTE, Ian Edward David SMITH, Stephen Andrew THOMSON, Joseph Wendell WILSON
  • Publication number: 20210198278
    Abstract: The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.
    Type: Application
    Filed: December 24, 2020
    Publication date: July 1, 2021
    Inventors: Andrea FAJDETIC, Maja MATANOVIC SKUGOR, Ivaylo Jivkov ELENKOV, Goran KRAGOL, Mirjana BUKVIC, Zorica MARUSIC ISTUK, Sanja KOSTRUN, Dinko ZIHER, Renata RUPCIC, Kristina BUTKOVIC, Marko DUKSI, Ivana OZIMEC LANDEK, Dijana PESIC, Antun HUTINEC, Milan MESIC, Gordon SAXTY, Visnja POLJAK
  • Patent number: 10919910
    Abstract: The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 16, 2021
    Assignee: FIDELTA D.O.O.
    Inventors: Andrea Fajdetic, Maja Matanovic Skugor, Ivaylo Jivkov Elenkov, Goran Kragol, Mirjana Bukvic, Zorica Marusic Istuk, Sanja Kostrun, Dinko Ziher, Renata Rupcic, Kristina Butkovic, Marko Duksi, Ivana Ozimec Landek, Dijana Pesic, Antun Hutinec, Milan Mesic, Gordon Saxty, Visnja Poljak
  • Publication number: 20200325134
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: February 19, 2020
    Publication date: October 15, 2020
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • Publication number: 20200165259
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 28, 2020
    Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
  • Publication number: 20200131153
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • Patent number: 10618895
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: April 14, 2020
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • Publication number: 20200017522
    Abstract: The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.
    Type: Application
    Filed: May 8, 2017
    Publication date: January 16, 2020
    Inventors: Andrea FAJDETIC, Maja MATANOVIC SKUGOR, Ivaylo Jivkov ELENKOV, Goran KRAGOL, Mirjana BUKVIC, Zorica MARUSIC ISTUK, Sanja KOSTRUN, Dinko ZIHER, Renata RUPCIC, Kristina BUTKOVIC, Marko DUKSI, Ivana OZIMEC LANDEK, Dijana PESIC, Antun HUTINEC, Milan MESIC, Gordon SAXTY, Visnja POLJAK
  • Patent number: 10519137
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: December 31, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Steven John Woodhead, Michael Reader, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Berthold Wroblowski, Alexandra Papanikos, Olivier Alexis Georges Querolle, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 10272087
    Abstract: The invention relates to new pteridine derivative compounds, of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 30, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher Charles Frederick Hamlett, Valerio Berdini, Christopher William Murray, Patrick René Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • Publication number: 20190002454
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Jeffrey Charles BOEHM, Thomas Glanmor DAVIES, Alison Jo-Anne WOOLFORD, Charlotte Mary GRIFFITHS-JONES, Hendrika Maria Gerarda WILLEMS, David NORTON, Gordon SAXTY, Thomas Daniel HEIGHTMAN, Tindy LI, Jeffrey K. KERNS, Roderick S. DAVIS, Hongxing YAN